Scimitar prudently performs analysis and creates quantitative models and estimates derived from our own research and due diligence without any assistance from the/any represented company. Scimitar’s estimates and models reflect “our” current judgment only; they are neither all-inclusive nor can they be guaranteed. “Our” analysis and models are subject to change based on share pricing, share/capitalization increases or decreases, regulatory status and certainly market conditions. Projecting the valuation of emerging healthcare companies can be truly “inexact”. In these current volatile market times; Scimitar has stepped back from making specific price targets. Valuation should be understood in terms of an objective quantitative model and a comprehensive qualitative explanation that enlightens investors to expectation and potential. Reiterating, “NO” part of our compensation is related to the specific valuation recommendations or views contained in this review.